







# Theoretical Description for Dexketoprofen Electrochemical Determination, Assisted by VO(OH) Composite with Polypyrrole

Volodymyr V. Tkach<sup>1,2,\*</sup> , Viktoriya V. Payentko<sup>3</sup> , Eugeny M. Demianenko<sup>3</sup> , Sílvio C. de Oliveira<sup>2</sup> , Yana G. Ivanushko<sup>4</sup> , Petro I. Yagodynets<sup>1,\*</sup> , Zholt O. Kormosh<sup>5</sup> 

<sup>1</sup> Chernivtsi National University, 58000, Kotsyubyns'ky Str. 2, Chernivtsi, Ukraine

<sup>2</sup> Universidade Federal de Mato Grosso do Sul, Av. Sen. Felinto. Müller, 1555, C/P. 549, 79074-460, Campo Grande, MS, Brazil

<sup>3</sup> Chuiko Institute of Surface Chemistry of National Academy of Sciences of Ukraine, 03164. Gen. Naumov Str., 17, Kyiv, Ukraine

<sup>4</sup> Bukovinian State Medical University, 58001, Teatralna Sq., 9, Chernivtsi Ukraine

<sup>5</sup> Eastern European National University, 43000, Voli Ave., 13, Lutsk, Ukraine

\* Correspondence: nightwatcher2401@gmail.com (V.V.T.); ved1988mid@rambler.ru (P.I.Y.);

Scopus Author ID 55758299100

Received: 24.11.2021; Accepted: 29.01.2022; Published: 14.03.2022

**Abstract:** An interesting electroanalytical process for dexketoprofen electrochemical determination over a polypyrrole-VO(OH)-modified electrode has been described. The electroanalytical process is realized by a cathodic reduction by two parallel mechanisms. The electroanalytical process kinetics is pH-dependent. The analysis of the mathematical model for this case has shown that the neutral and mildly acidic media is slightly more favorable to dexketoprofen electrochemical determination. The steady-state stability and electroanalytical efficiency of the process have been proven. The process may be used *in vitro* and *in vivo* to evaluate the drug delivery efficiency.

**Keywords:** dexketoprofen; electrochemical sensors; vanadium (III) oxyhydroxide; polypyrrole; stable steady-state.

© 2022 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Dexketoprofen (dextrorotary ketoprofen, Fig. 1) [1–4] is widely used as a non-steroid painkiller for a short-time treatment of mild to moderate pain. The chiral switch from ketoprofen to dexketoprofen enhances the drug's therapeutical efficiency.




Figure 1. Dexketoprofen.


The side effects of dexketoprofen include dizziness, nausea, vomiting [5–10]. Also, it may increase the alcohol and sedative drugs action. Moreover, it may be intolerant in certain persons, which is why the development of an efficient method for dexketoprofen determination is actual [11,12].

Considering the presence of the electroactive groups, we may conclude that the electroanalytical methods apply to dexketoprofen determination [13–16]. Moreover, the cathodic processes are more convenient, so the vanadium (III) oxyhydroxide may be suitable for cathode modifiers. To enhance the VO(OH) efficiency in the electroanalytical process, it is used in the form of nanoparticles, stabilized by conducting a polymer layer [17–21].

Nevertheless, we can't proceed with the practical use of the electroanalytical system without the theoretical mechanistic stability investigation of its behavior. This analysis includes the probability of the instabilities, typical for electrooxidation and electropolymerization processes [22–24]. Also, this analysis includes the “virtual” comparison of the electroanalytical systems. Therefore, we analyze the VO(OH)-doped conducting polymer electrode efficiency in the dexketoprofen electrochemical determination in this work. This analysis includes the mechanism suggestion and analysis by means of the correspondent mathematical mode like also the virtual comparison of this system with that of the similar electroanalytical processes [25 – 34]

## 2. Materials and Methods

Dexketoprofen molecule contains two moieties capable of reducing electrochemically. As for the carbonyl, moiety is reduced at the first turn, yielding the correspondent hydroxy acids. It is thereby reduced by the carboxyl group, yielding the correspondent diol (Fig. 2):



**Figure 2.** The scheme of dexketoprofen reduction.

As for polypyrrole, it plays a dual role in the composite, stabilizing the VO(OH) nanoparticles and providing electron transfer mediation.

Therefore, to describe the behavior of this system, we introduce three variables:

$c$  – dexketoprofen concentration in the pre-surface layer;

$c^*$  - dexketoprofen primary reduced form concentration in the pre-surface layer;

$v$  – vanadium dioxide surface coverage degree.

Taking some assumptions [27 – 34], we expose the balance differential equation-set for this system as:

$$\begin{cases} \frac{dc}{dt} = \frac{2}{\delta} \left( \frac{\Delta}{\delta} (c_0 - c) - r_1 \right) \\ \frac{dc^*}{dt} = \frac{2}{\delta} (r_1 - r_2) \\ \frac{dv}{dt} = \frac{1}{V} (r_1 + r_2 - r_r) \end{cases} \quad (1)$$

Herein,  $\Delta$  is the diffusion coefficient,  $c_0$  is drug bulk concentration,  $V$  is vanadium dioxide maximal surface concentration, and the parameters  $r$  are the correspondent reaction rates, calculated as:

$$r_1 = k_1 c (1 - v)^2 \exp(-ac) \quad (2)$$

$$r_2 = k_1 c * (1 - v)^4 \exp(-bc *) \quad (3)$$

$$r_r = k_r v \exp\left(-\frac{F\varphi_0}{RT}\right) \quad (4)$$

In which the parameters  $k$  are the correspondent reaction rate constants,  $F$  is the Faraday number,  $\varphi_0$  is the zero-charge potential related potential slope,  $R$  is the universal gas constant and  $T$  is the reactor absolute temperature.

As for the parameters  $a$  and  $b$ , they describe the DEL influence of the transformation of the ionic form on the chemical stage and, taking into account the acidic nature of the analyte; their values are conditioned to (5):

$$a, b \begin{cases} = 0, & pH \leq 7 \\ \neq 0, & pH > 7 \end{cases} \quad (5)$$

Describing the pH-dependent feature of the ionic transformations on the chemical stage of the electroanalytical process.

As for the process, its behavior is expected to be pH-dependent. The oscillatory behavior in this system is expected to be less probable in neutral and acidic media and more probable in alkaline media. Nevertheless, the electroanalytical process is expected to be efficient, as shown below.

### 3. Results and Discussion

To describe the system's behavior with dexketoprofen VO(OH)-PPy assisted electrochemical determination, we analyze the balance differential equation-set (1) using linear stability theory and bifurcation analysis. The steady-state Jacobian functional matrix members for it may be described as:

$$\begin{pmatrix} a_{11} & a_{12} & a_{13} \\ a_{21} & a_{22} & a_{23} \\ a_{31} & a_{32} & a_{33} \end{pmatrix} \quad (6)$$

in which:

$$a_{11} = \frac{2}{\delta} \left( -\frac{\Delta}{\delta} - k_1 (1 - v)^2 \exp(-ac) + ak_1 c (1 - v)^2 \exp(-ac) \right) \quad (7)$$

$$a_{12} = 0 \quad (8)$$

$$a_{13} = \frac{2}{\delta} (2k_1 c (1 - v) \exp(-ac)) \quad (9)$$

$$a_{21} = \frac{2}{\delta} (k_1 (1 - v)^2 \exp(-ac) - ak_1 c (1 - v)^2 \exp(-ac)) \quad (10)$$

$$a_{22} = \frac{2}{\delta} (bk_1 c * (1 - v)^4 \exp(-bc *) - k_1 (1 - v)^4 \exp(-bc *)) \quad (11)$$

$$a_{23} = \frac{2}{\delta} (4k_1 c * (1 - v)^3 \exp(-bc *) - 2k_1 c (1 - v) \exp(-ac)) \quad (12)$$

$$a_{31} = \frac{1}{v} (2k_1 c (1 - v) \exp(-ac) - ak_1 c (1 - v)^2 \exp(-ac)) \quad (13)$$

$$a_{32} = \frac{1}{v} (2k_1 c (1 - v) \exp(-ac) - bk_1 c * (1 - v)^4 \exp(-bc *)) \quad (14)$$

$$a_{33} = \frac{1}{v} \left( -2k_1 c (1 - v) \exp(-ac) - 4k_1 c * (1 - v)^3 \exp(-bc *) - k_r \exp\left(-\frac{F\varphi_0}{RT}\right) + jk_r v \exp\left(-\frac{F\varphi_0}{RT}\right) \right) \quad (15)$$

Taking into account the Jacobian main diagonal elements (7), (11), and (15), we may conclude that the oscillatory behavior for this system is possible. Moreover, considering the

conditions (5), we may conclude that it will be more probable for alkaline pH than neutral and acidic.

Really, if the element  $jk_r v \exp\left(-\frac{F\phi_0}{RT}\right) > 0$ , if  $j > 0$ , typical for all the similar systems [25 – 28] describes the oscillatory behavior on the electrochemical stage at both alkaline and non-alkaline pH, the elements  $ak_1c(1 - v)^2 \exp(-ac) > 0$  and  $bk_1c * (1 - v)^4 \exp(-bc *) > 0$ , if  $a, b > 0$ , describe the oscillatory behavior caused by ionic forms transformations on the chemical stage. As in neutral and acidic media, the dexketoprofen molecule is less ionized, the DEL is less affected, and this effect may be neglected. The values of  $a$  and  $b$  will thus be equal to nil, reducing the probability of the oscillatory behavior.

As for the steady-state stability, its region augments neutral and mildly acidic media and diminishes the alkaline media. Applying the Routh-Hurwitz criterion to the equation-set (1), rewriting the matrix determinant as (16):

$$\frac{4}{\delta^2 V} \begin{vmatrix} -\kappa - \mathcal{E} & 0 & \Lambda \\ \mathcal{E} & -\Sigma & P - \Lambda \\ \mathcal{E} & \Sigma & -\Lambda - P - \Omega \end{vmatrix} \quad (16)$$

and investigating the  $\text{Det } J < 0$  requisite, salient from the criterion, we obtain the steady-state stability condition, expressed as (17):

$$2\Lambda\mathcal{E}\Sigma - (\kappa + \mathcal{E})(2\Sigma\Lambda + \Sigma\Omega) < 0 \quad (18),$$

Conveniently rewritten as (19)

$$(\kappa + \mathcal{E})(2\Sigma\Lambda + \Sigma\Omega) > 2\Lambda\mathcal{E}\Sigma \quad (19)$$


Indicating either diffusion or kinetically controlled electroanalytical efficient process. The less alkaline is the media, the vaster is the topological area, correspondent to the realization of the condition (19). Also, as no side reaction compromising the analyte and(or) modifier stability occur in this process, the steady-state stability will correspond to the linear dependence between electrochemical parameter and concentration.

As the pH value of the inflamed tissue tends to be mildly acidic, this sensor may easily be used *in vivo* in order to monitor the drug delivery and release.

The detection limit is defined by the *monotonic instability*, describing the margin between the stable and unstable states. Its condition is  $\text{Det } J = 0$ , or (20).

$$(\kappa + \mathcal{E})(2\Sigma\Lambda + \Sigma\Omega) = 2\Lambda\mathcal{E}\Sigma \quad (20)$$

The lowermost pH limit for this model is correspondent to the pH=3, in which VO(OH) becomes dissolved (21):



The VO(OH) dissolution will be thereby accompanied by both surface and DEL instabilities. This case will be described in our next papers.

#### 4. Conclusions

The theoretical analysis for the possibility of VO(OH) – PPy-assisted dexketoprofen electrochemical determination let us conclude that the system is more efficient in neutral and acidic media and less efficient in alkaline solutions. As for the oscillatory behavior is more probable in alkaline solutions and less probable in the acidic. The system's behavior permits us to use this electroanalytical process for drug release and delivery monitoring.

#### Funding

This research received no external funding.

## Acknowledgments

This research has no acknowledgment.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Mejía-Abril, G.; Zubiaur, P.; Navares-Gómez, M.; Villalpalos-García, G.; Román, M.; Ochoa, D.; Abad-Santos, F. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. *Frontiers in Pharmacology* **2021**, *12*, <https://doi.org/10.3389/fphar.2021.660639>.
2. Hanna, M.; Montero, A.; Perrot, S.; Varrassi, G. Tramadol/Dexketoprofen Analgesic Efficacy Compared with Tramadol/Paracetamol in Moderate to Severe Postoperative Acute Pain: Subgroup Analysis of a Randomized, Double-Blind Parallel Group Trial—DAVID Study. *Pain Ther.* **2021**, *10*, 485–503, <https://doi.org/10.1007/s40122-020-00228-7>.
3. Erdil, A.; Demirsoy, M.S.; Çolak, S.; Duman, E.; Sümbül, O.; Aygun, H. The effect of dexketoprofen trometamol on WAG/Rij rats with absence epilepsy (dexketoprofen in absence epilepsy). *Neurological research* **2021**, *43*, 1116–1125, <https://doi.org/10.1080/01616412.2021.1952510>.
4. Vallecillo, C.; Vallecillo-Rivas, M.; GÁLvez, R.; Vallecillo-Capilla, M.; Olmedo-Gaya, M.V. Analgesic Efficacy of Tramadol/Dexketoprofen vs Ibuprofen after Impacted Lower Third Molar Extraction: a Randomized Controlled Clinical Trial. *J. Evid. Based Dent. Pract.* **2021**, *21*, <https://doi.org/10.1016/j.jebdp.2021.101618>.
5. Nikonov, V.V.; Lyzohub, K.I. Principle of Choosing an Analgesic Depending on the Intensity of Pain. *Medytsyna Nevidklad. Stan.Emergency Medicine* **2021**, *17*, 6–9, <https://doi.org/10.22141/2224-0586.17.3.2021.234795>.
6. Başkor, A.; Tok, Y.P.; Mesut, B.; Özsoy, Y.; Uçar, T. Estimating the Optimal Dexketoprofen Pharmaceutical Formulation with Machine Learning Methods and Statistical Approaches. *Healthcare Inf. Res.* **2021**, *27*, 279–286, <https://doi.org/10.4258/hir.2021.27.4.279>.
7. Franco de la-Torre, L.; Alonso-Castro, Á.J.; Zapata-Morales, J.R.; Rivas-Carrillo, J.D.; Vidaurrazaga-Lugo, J.; Partida-Castellanos, E.M.; Granados-Soto, V.; Isiordia-Espinoza, M.A. Antinociception and Less Gastric Injury with the Dexketoprofen-Tapentadol Combination in Mice. *Fund. Clin. Pharm.* **2021**, *35*, 371–378, <https://doi.org/10.1111/fcp.12625>.
8. Rossi, P.; Paoli, P.; Milazzo, S.; Chelazzi, L.; Giovannoni, M.P.; Guerrini, G.; Ienco, A.; Valleri, M.; Conti, L. A Combined Crystallographic and Computational Study on Dexketoprofen Trometamol Dihydrate Salt. *Crystals* **2020**, *10*, <https://doi.org/10.3390/cryst10080659>.
9. Lakeev, A.P.; Yanovskaya, E.A.; Bryushinina, O.S. *et al.* The Methodology for Dexketoprofen Trometamol Determination in Human Plasma and its Validation. *J. Anal. Chem.* **2021**, *76*, 442–453, <https://doi.org/10.31857/S0044450221050133>.
10. Akbas, I.; Kocak Meryem, B.; Kocak Abdullah, O.; Gur Sultan Tuna, A.; Dogruyol, S.; Demir, M.; Cakir, Z. Intradermal mesotherapy versus intravenous dexketoprofen for the treatment of migraine headache without aura: a randomized controlled trial. *Annals of Saudi Medicine* **2021**, *41*, 127–134, <https://doi.org/10.5144/0256-4947.2021.127>.
11. Mititelu-Tartau, L.; Bogdan, M.; Pricop, D.A.; Buca, B.R.; Hilitanu, L.; Pauna, A.-M.; Dijmarescu, L.A.; Popa, E.G. Biocompatibility and Pharmacological Effects of Innovative Systems for Prolonged Drug Release Containing Dexketoprofen in Rats. *Polymers* **2021**, *13*, <https://doi.org/10.3390/polym13071010>.
12. Gur, M.; Ulu, M.B.; Caliskan, S.T.; Ozturk, K.; Akdeniz, E. Dexketoprofen vs. Tamsulosin vs. Silodosin vs. Tadalafil as Medical Expulsive Therapy for Distal Ureteral Stones in Men. *Journal of the College of Physicians and Surgeons--Pakistan* **2021**, *31*, 947–952, <https://doi.org/10.29271/jcpsp.2021.08.947>.
13. Torrinha, Á.; Martins, M.; Tavares, M.; Delerue-Matos, C.; Morais, S. Carbon paper as a promising sensing material: Characterization and electroanalysis of ketoprofen in wastewater and fish. *Talanta* **2021**, *226*, <https://doi.org/10.1016/j.talanta.2021.122111>.
14. Coban, O.; Degim, Z. Development and Validation of Highly Selective Method for The Determination of Imatinib Mesylate and Dexketoprofen Trometamol Combination in Three Different Media. *Brazilian J. Pharm. Sci.* **2020**, *56*, <http://dx.doi.org/10.1590/s2175-97902019000418583>.
15. Shoshmina, O.V.; Gureyeva, S.M.; Vronska, L.V. Study on the Influence of Excipients on Pharmaceutical Technological Properties of Tablet Cores of Dexketoprofen. *Pharm. Technol.* **2019**, *1*, 53–63, <https://doi.org/10.32352/0367-3057.1.19.05>.
16. Ozturk, A.A.; Banderas, L.M.; Cayero Otero, M.D.; Yenilmez, E.; Senel, B.; Yazan, Y. Dexketoprofen Trometamol-Loaded Poly-Lactic-co-Glycolic Acid (PLGA) Nanoparticles: Preparation, *In Vitro* Characterization and Cytotoxicity. *Trop. J. Pharm. Res.* **2019**, *18*, 1–11, <https://doi.org/10.4314/tjpr.v18i1.1>.



17. Liu, X.; Liu, J. Biosensors and Sensors for Dopamine Detection. *View* **2021**, *2*, <https://doi.org/10.1002/VIW.20200102>.
18. KKarthika, A.; Ramasamy Raja, V.; Karuppasamy, P.; Suganthi, A.; Rajarajan, M. A Novel Electrochemical Sensor for Determination of Hydroquinone in Water Using FeWO<sub>4</sub>/SnO<sub>2</sub> Nanocomposite Immobilized Modified Glassy Carbon Electrode. *Arab. J. Chem.* **2020**, *13*, 4065–4081, <https://doi.org/10.1016/j.arabjc.2019.06.008>.
19. Kumar, Y.; Vashistha, V.K.; Das, D.K. Synthesis of Perovskite-type NdFeO<sub>3</sub> nanoparticles and used as electrochemical sensor for detection of paracetamol. *Lett. Appl. Nanobiosci.* **2020**, *9*, 866–869. <https://doi.org/10.33263/LIANBS91.866869>.
20. Sá, A.C.d.; Barbosa, S.C.; Raymundo-Pereira, P.A.; Wilson, D.; Shimizu, F.M.; Raposo, M.; Oliveira, O.N. Flexible Carbon Electrodes for Electrochemical Detection of Bisphenol-A, Hydroquinone and Catechol in Water Samples. *Chemosensors* **2020**, *8*, <https://doi.org/10.3390/chemosensors8040103>.
21. Koçak, Ç.C.; Koçak, S. Enhanced Electrochemical Determination of Catechol and Hydroquinone Based on Pd Nanoparticles/Poly(Taurine) Modified Glassy Carbon Electrode. *Electroanalysis* **2020**, *32*, <https://doi.org/10.1002/elan.201900500>.
22. Yang, P.; Zhang, S.; Chen, X.; Liu, X.; Wang, Z.; Li, Y. Recent developments in polydopamine fluorescent nanomaterials. *Materials Horizons* **2020**, *7*, 746–761, <https://doi.org/10.1039/c9mh01197h>.
23. Ziyatdinova, G.; Guss, E.; Morozova, E.; Budnikov, H.; Davletshin, R.; Vorobev, V.; Osin, Y. Simultaneous voltammetric determination of gallic and ellagic acids in cognac and brandy using electrode modified with functionalized SWNT and poly(pyrocatechol violet). *Food Analytical Methods* **2019**, *12*, 2250–2261, <https://doi.org/10.1007/s12161-019-01585-6>.
24. Das, I.; Goel, N.; Agrawal, N.R.; Gupta, S.K. Growth patterns of dendrimers and electric potential oscillations during electropolymerization of pyrrole using mono-and mixed surfactants. *J. Phys. Chem. B* **2010**, *114*, 12888–12896, <https://doi.org/10.1021/jp105183q>.
25. Das, I.; Goel, N.; Gupta, S.K.; Agrawal, N.R. Electropolymerization of pyrrole: Dendrimers, nano-sized patterns and oscillations in potential in presence of aromatic and aliphatic surfactants. *J. Electroanal. Chem.* **2012**, *670*, 1–10, <https://doi.org/10.1016/j.jelechem.2012.01.023>.
26. Tkach, V.V.; Kushnir, M.V.; Skrypska, O.V.; Ivanushko, Y.G.; de Oliveira, S.C.; Yagodynets, P.I.; Iuganska, O.V.; Kormosh, Z.O. La descripción teórica de la electropolimerización de compuestos hidroquinónicos, obtenidos electroquímicamente. *South Florida J. Dev.* **2021**, *2*, 2552–2561, <https://doi.org/10.46932/sfjdv2n2-111>.
27. Tkach, V.V.; Kushnir, M.V.; de Oliveira, S.C.; Ivanushko, Y.G.; Tkach, V.O.; Mytrofanova, H.Y.; Zadoia, A.O.; Yagodynets, P.I.; Kormosh, Z.O.; Iuganska, O.V. Theoretical Description for Copper (II) Electrochemical Determination and Retention on a 1(2-pyridilazo)-2-naphthole-Modified Anode. *Lett. Appl. NanoBioSci.* **2021**, *10*, 2078–2084, <https://doi.org/10.33263/LIANBS102.20782084>.
28. Tkach, V.; Kushnir, M.; Ahafonova, O.; Mytchenok, M.; Bocharov, A.; Kovalchuk, P.; de Oliveira, S.; Yagodynets, P.; Kormosh, Z.; Reis, L. The theoretical description for the electrochemical determination of 4-4-dihydroxyazobenzene, assisted by a composite of squarainedyne with cobalt (iii) oxyhydroxide in pair with cobalt (iv) oxide. *Appl. J. Env. Eng. Sci.* **2021**, *7*, 55–62, <https://doi.org/10.48422/IMIST.PRSM/ajees-v7i1.23046>.
29. Guo, T.; Chang, T.; Akinay, Y. Synthesis of PPy@Ba<sub>0.5</sub>Sr<sub>0.5</sub>Fe<sub>12</sub>O<sub>19</sub>/CNFs by Reverse In-situ Polymerization Method for Microwave Absorption Applications. *Synth. Metals*, **2020**, *266*, <https://doi.org/10.1016/j.synthmet.2020.116387>.
30. Zhou, J.; Liu, D.; Xiong, Y.; Akinay, Y. A Novel Approach to Prepare Polyaniline/Polypyrrole@Cu-BTC/NH<sub>2</sub>-MIL-101(Fe) MOFs for Electromagnetic Wave Absorption. *Ceram Int.* **2020**, *46*, 19758–19766, <https://doi.org/10.1016/j.ceramint.2020.05.006>.
31. Akinay, Y.; Hayat, F.; Colak, B. Absorbing Properties and Structural Design of PVB/Fe<sub>3</sub>O<sub>4</sub> Nanocomposite. *Mater. Chem. Phys.* **2019**, *229*, 460–466, <https://doi.org/10.1016/j.matchemphys.2019.03.039>.
32. Cao, Y.; Mohamed, A.M.; Mousavi, M.; Akinay, Y. Poly(pyrrole-co-styrene sulfonate)-encapsulated MWCNT/Fe–Ni alloy/NiFe<sub>2</sub>O<sub>4</sub> nanocomposites for microwave absorption. *Mater. Chem. Phys.* **2021**, *259*, <https://doi.org/10.1016/j.matchemphys.2020.124169>.
33. Niu, H.; Liu, P.; Qin, F.; Liu, X.; Akinay, Y. PEDOT coated Cu-BTC metal-organic frameworks decorated with Fe<sub>3</sub>O<sub>4</sub> nanoparticles and their enhanced electromagnetic wave absorption. *Materials Chemistry and Physics* **2020**, *253*, <https://doi.org/10.1016/j.matchemphys.2020.123458>.
34. Akinay, Y.; Hayat, F. Synthesis and Microwave Absorption Enhancement of BaTiO<sub>3</sub> Nanoparticle/Polyvinilbutyral Composites. *J. Comp. Mat.* **2019**, *535*, 593–601, <https://doi.org/10.1177/0021998318788144>.